Continuing the strategy of focusing on core businesses
AXIO Data Group today announced that it has completed the sale of IASIST to IMS Health, a leading provider of information and technology services to the healthcare industry. The financial consideration is undisclosed.
IASIST is a leading healthcare benchmarking company serving customers in Spain, Portugal and Chile. Built upon knowledge from a highly specialized team and the largest clinical databases, IASIST offers health care providers, payers and the health industry the clinical and economic information required to improve quality and efficiency in their organizations and the services provided to their customers.
Henry Elkington, CEO of AXIO commented, “This transaction continues our process of focusing. Our main continuing healthcare business is Vidal Group, the market leader in drug information systems in Europe.
Iasist is the clear leader in its niche and we are pleased to have supported its expansion into Latin America. We are confident that IMS will prove a synergistic, long-term home for the business. ”
Notes to Editors:
AXIO Data Group operates a portfolio of market-leading information businesses providing critical, and often industry-standard, information and tools. Operating in over 17 countries worldwide, the group’s brands include Vidal in the healthcare sector, TechInsights in the intellectual property sector, OAG in the global aviation sector and RISI in the forest products sector.
AXIO is owned by funds managed by Electra Partners LLP. Electra is an independent private equity fund manager with more than 30 years’ experience. As of 30th September, 2015, the firm had funds under management of £1.8 billion. For more information, visit www.axiogroup.net or www.electrapartners.com.
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. IMS Health’s 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes.
IMS Health’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.